Close
This MSc offers a comprehensive guide to all aspects of modern day drug design. It is taught by research scientists, clinicians and industry experts. Our graduates have progressed to undertake or obtain PhDs or medical studentships, or have found employment in both the private and public sector.
Key information
Programme starts
September 2021
Modes and duration
Part-time is on-site for two years.
Application dates
Tuition fees (2021/22)
Note on fees:
The tuition fees shown are for the year indicated above. Fees for subsequent years may increase or otherwise vary. Further information on fee status, fee increases and the fee schedule can be viewed on the UCL Students website: ucl.ac.uk/students/fees. Fees for flexible, modular study are charged pro-rata to the appropriate full-time Master's fee taken in an academic session.
Entry requirements
A minimum of a lower second-class Bachelor's degree in a relevant subject from a UK university or an overseas qualification of an equivalent standard.
English language requirements
If your education has not been conducted in the English language, you will be expected to demonstrate evidence of an adequate level of English proficiency.
The English language level for this programme is: Standard
UCL Pre-Master's and Pre-sessional English courses are for international students who are aiming to study for a postgraduate degree at UCL. The courses will develop your academic English and academic skills required to succeed at postgraduate level. International Preparation Courses
Further information can be found on our English language requirements page.
International students
Country-specific information, including details of when UCL representatives are visiting your part of the world, can be obtained from the International Students website.
International applicants can find out the equivalent qualification for their country by selecting from the list below.
Select your country:
About this degree
The programme covers all aspects of drug design, including genomics, bioinformatics, structural biology, cheminformatics, molecular modelling and fragment-based drug design, drug target selection, intellectual property and marketing. New therapies and research areas such as antibodies, siRNA, stem cells and high throughput screening are covered. Students will develop essential skills such as research methods and techniques of drug design.
Find out more about this degree: WIBR Teaching
Students undertake modules to the value of 180 credits.
The programme consists of eight core modules (120 credits) and a research project (60 credits).
A Postgraduate Diploma (120 credits) is also offered.
A Postgraduate Certificate (60 credits) is also offered
Upon successful completion of 180 credits, you will be awarded a MSc in Drug Design. Upon successful completion of 120 credits, you will be awarded a PG Dip in Drug Design. Upon successful completion of 60 credits, you will be awarded a PG Cert in Drug Design.
Please note that the list of modules given here is indicative. This information is published a long time in advance of enrolment and module content and availability is subject to change.
Compulsory modules
- Bioinformatics and Structural Biology
- Target Identification and High Throughput Screening
- Cheminformatics and Computer Drug Design
- Biological Molecules as Therapeutics - Antibodies, siRNA, and Stem Cells
- Biophysical Screening Methods, Protein NMR and Phenotypic Screening
- Fragment Based Drug Design (FBDD)
- Target Selection - Scientific Grounds
- Target Selection - Commercial and Intellectual Property
Optional modules
There are no optional modules for this programme.
Dissertation/report
All MSc students undertake an independent research project which can take the form of a wet lab or dry lab computational or modelling based project.
Teaching and learning
The programme is delivered through a combination of lectures, tutorials, self study, practical sessions and discussion groups. The research project forms one third of the programme. Each of the taught modules is assessed by unseen written examination (50%) and coursework (50%). The research project is assessed by the dissertation and viva.
Additional costs
For more information on additional costs for prospective students please go to our estimated cost of essential expenditure at Accommodation and living costs.
Accessibility
Details of the accessibility of UCL buildings can be obtained from AccessAble accessable.co.uk. Further information can also be obtained from the UCL Student Support & Wellbeing team.
Funding
Division of Medicine Bursaries are not applicable to the MSc Obesity and Clinical Nutrition, MSc Clinical and Public Health Nutrition, MSc Eating Disorders and Clinical Nutrition or MSc Drug Design.
Students should check UCL's website for information on broader schemes.
For a comprehensive list of the funding opportunities available at UCL, including funding relevant to your nationality, please visit the Scholarships and Funding website.
Careers
The programme will provide a good background for students looking to establish a career in drug design/discovery and related industries (biotech, pharma, national research laboratories and NHS agencies), and for industry professionals seeking to gain a greater understanding of new methodology. The knowledge and transferable skills delivered will also be useful for those intent on further PhD or medical studies.
Employability
Graduates from this programme have progressed to PhD/medical studentships at different universities and research institutes around the world, including Oxford, UCL, Grenoble, EMBL, and in the USA and China. Many alumni have secured positions in research teaching and technical sales in the private and public sectors.
Why study this degree at UCL?
UCL is ranked 7th in the QS World University Rankings 2018 and is located in the centre of one of the world's finest cities. UCL is one of Europe's best and largest centres for biomedical research.
This degree taken at the internationally renowned UCL Division of Medicine is supported by the Wolfson Institute for Biomedical Research, where we have pioneered multidisciplinary research with a particular emphasis on translating that research into useful clinical benefit. Our research expertise includes: medicinal chemistry, computational drug design, neuronal development and signalling, cell cycle control, intensive care medicine, stem cells, mitochondrial biology and cancer.
Find out more about this degree: WIBR Teaching
Department: Division of Medicine
Application and next steps
Applications
Students are advised to apply as early as possible due to competition for places. Those applying for scholarship funding (particularly overseas applicants) should take note of application deadlines.
This programme requires two references. Further information regarding references can be found in our How to apply section.
There is an application processing fee for this programme of £90 for online applications and £115 for paper applications. Further information can be found at: ucl.ac.uk/prospective-students/graduate/taught/application.
Who can apply?
This MSc is suitable for life science graduates in biological sciences, chemical sciences and pharmacy who wish to obtain a broad understanding of the drug design process, either to establish a career in drug design and related industries, or to pursue further PhD or medical studies in this field.
Application deadlines
- All applicants
- 31 May 2021
For more information see our Applications page.
Apply nowWhat are we looking for?
When we assess your application we would like to learn:
- why you want to study Drug Design at graduate level
- why you want to study Drug Design at UCL
- what particularly attracts you to this programme
- how your academic and professional background meets the demands of this programme
- where you would like to go professionally with your degree
Together with essential academic requirements, the personal statement is your opportunity to illustrate whether your reasons for applying to this programme match what the programme will deliver.
UCL is regulated by the Office for Students.
Page last modified on 28 August 2021
